Among patients with severe community-acquired pneumonia being treated in the ICU, those who received hydrocortisone had a lower risk of death by day 28 than those who received placebo. (Funded by the French Ministry of Health; CAPE COD ClinicalTrials.gov number, NCT02517489.).

Mark Helpful

Bookmark

Relay

Mark Helpful

Bookmark

Relay

Cite This Study

Dequin et al. (Tue,) studied this question.

synapsesocial.com/papers/69d94685da3af5b1d083625a https://doi.org/https://doi.org/10.1056/nejmoa2215145

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience2020 · 7 citations
2Hydrocortisone Infusion for Severe Community-acquired Pneumonia2004 · 865 citations
3Hydrocortisone plus Fludrocortisone for Adults with Septic Shock2018 · 891 citations
4A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia1997 · 4,667 citations
5Adjunctive Glucocorticoid Therapy in Patients with Septic Shock2018 · 1,001 citations

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience2020 · 7 citations
2Hydrocortisone Infusion for Severe Community-acquired Pneumonia2004 · 865 citations
3Hydrocortisone plus Fludrocortisone for Adults with Septic Shock2018 · 891 citations
4A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia1997 · 4,667 citations
5Adjunctive Glucocorticoid Therapy in Patients with Septic Shock2018 · 1,001 citations